ID   U-CH2
AC   CVCL_4989
SY   UCH-2; UCH2
DR   ATCC; CRL-3218
DR   Cell_Model_Passport; SIDM01185
DR   Cosmic; 2663858
DR   Cosmic-CLP; 1503373
DR   DepMap; ACH-002204
DR   DSMZ; ACC-749
DR   DSMZCellDive; ACC-749
DR   GEO; GSM1670565
DR   GEO; GSM1673847
DR   GEO; GSM1673848
DR   PharmacoDB; UCH2_1627_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54973617
RX   PubMed=21253487;
RX   PubMed=26183925;
RX   PubMed=27102572;
RX   PubMed=27397505;
RX   PubMed=28515451;
RX   PubMed=28835717;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://www.chordomafoundation.org/research/disease-models/u-ch2/
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/UCH1_Crawford_protocol.pdf
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 4 days (PubMed=26183925); ~5-7 days (DSMZ=ACC-749); 3 days (Chordoma_Foundation).
CC   HLA typing: A*11:01; B*07; C*07:02; DQA1*02:01; DQB1*03; DRB4*01:03N (Chordoma_Foundation).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.92%; East Asian, North=0%; East Asian, South=0.34%; South Asian=1.36%; European, North=67.93%; European, South=29.44% (PubMed=30894373).
ST   Source(s): ATCC; Cosmic-CLP; DSMZ; PubMed=21253487; PubMed=26183925; PubMed=27102572; PubMed=28835717
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D10S1248: 13,16
ST   D12S391: 18,19
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 12,18 (PubMed=26183925; PubMed=27102572; PubMed=28835717)
ST   D18S51: 12,17.3 (DSMZ)
ST   D19S433: 15.2,17 (PubMed=26183925; PubMed=27102572)
ST   D19S433: 16,17 (DSMZ)
ST   D1S1656: 14.3,15
ST   D21S11: 29,30
ST   D22S1045: 15
ST   D2S1338: 24
ST   D2S441: 10,11.3
ST   D3S1358: 17
ST   D5S818: 10,11
ST   D7S820: 8,12
ST   D8S1179: 13
ST   FGA: 21,22.2
ST   Penta D: 12,13
ST   Penta E: 12,15
ST   TH01: 6 (Cosmic-CLP)
ST   TH01: 6,9.3 (PubMed=21253487)
ST   TH01: 9.3 (ATCC; DSMZ; PubMed=26183925; PubMed=27102572)
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C129927; Sacral chordoma
DI   ORDO; Orphanet_178; Chordoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   72Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 28
//
RX   PubMed=21253487; DOI=10.1155/2010/630129;
RA   Bruderlein S., Sommer J.B., Meltzer P.S., Li S.-F., Osada T., Ng D.,
RA   Moller P., Alcorta D.A., Kelley M.J.;
RT   "Molecular characterization of putative chordoma cell lines.";
RL   Sarcoma 2010:630129.1-630129.14(2010).
//
RX   PubMed=26183925; DOI=10.1158/0008-5472.CAN-14-3270;
RA   von Witzleben A., Goerttler L.T., Marienfeld R., Barth H., Lechel A.,
RA   Mellert K., Bohm M., Kornmann M., Mayer-Steinacker R., von Baer A.,
RA   Schultheiss M., Flanagan A.M., Moller P., Bruderlein S., Barth T.F.E.;
RT   "Preclinical characterization of novel chordoma cell systems and their
RT   targeting by pharmocological inhibitors of the CDK4/6 cell-cycle
RT   pathway.";
RL   Cancer Res. 75:3823-3831(2015).
//
RX   PubMed=27102572; DOI=10.1002/path.4729;
RA   Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H.,
RA   Zuercher W.J., Turlais F., Ye H.-T., Leite A.P., Smith J.A., Leithner A.,
RA   Moller P., Bruderlein S., Guppy N., Amary F., Tirabosco R.,
RA   Strauss S.J., Pillay N., Flanagan A.M.;
RT   "EGFR inhibitors identified as a potential treatment for chordoma in a
RT   focused compound screen.";
RL   J. Pathol. 239:320-334(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28515451; DOI=10.1038/s41598-017-02174-5;
RA   Jager D., Barth T.F.E., Bruderlein S., Scheuerle A., Rinner B.,
RA   von Witzleben A., Lechel A., Meyer P., Mayer-Steinacker R., von Baer A.,
RA   Schultheiss M., Wirtz C.R., Moller P., Mellert K.;
RT   "HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and
RT   sacral chordomas.";
RL   Sci. Rep. 7:2032-2032(2017).
//
RX   PubMed=28835717; DOI=10.1038/s41598-017-10044-3;
RA   Bosotti R., Magnaghi P., Di Bella S., Cozzi L., Cusi C., Bozzi F.,
RA   Beltrami N., Carapezza G., Ballinari D., Amboldi N., Lupi R.,
RA   Somaschini A., Raddrizzani L., Salom B., Galvani A., Stacchiotti S.,
RA   Tamborini E., Isacchi A.;
RT   "Establishment and genomic characterization of the new chordoma cell
RT   line Chor-IN-1.";
RL   Sci. Rep. 7:9226-9226(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//